Clinical Profile And Survival Outcomes in Pediatric Germ Cell Tumors: Single Centre Experience
Main Article Content
Abstract
Objective: This study was designed to assess the clinical features and survival outcomes of pediatric Germ cell tumors (GCTs) in our center.
Materials and Methods: All newly diagnosed cases of GCTs in the Pediatric Oncology Department, Combined Military Hospital, Rawalpindi, between 1st January 2012 and 31st December 2023 were evaluated prospectively.
Results: During the study period, 100 cases were treated for Germ Cell tumors. The cases with central nervous system GCTs, those who relapsed after receiving initial treatment at another institute, and those who lost to follow-up were excluded from this study The data of the remaining 86 cases was analyzed. The median age of the patients at presentation was 24 months (IQR: 15 to 66). The male-to-female ratio was 1.5:1. The most common symptom at presentation in males was scrotal swelling (68.4%), while in females, it was abdominal pain (55.1%). The most common anatomic site at presentation was gonadal n=57 (66.3% with 46.5% cases in the testis and 19.8% in the ovaries). Yolk sac tumor was the commonest type in 51(59.3%), followed by teratoma in 17(19.8%). The disease was metastatic in 29(33.7%) cases, and the most frequent site of metastasis was pulmonary 44.8%.
The most common stage at presentation according to COG staging is stage 1(39.5%), followed by stage 4 (32.6%), and upon applying MaGIC risk group classification, Standard Risk 1 was the most common type, followed by Low-Risk type in 60.5% and 36% cases respectively. Serum Tumor Markers (STMs), alpha-FP, and beta-HCG were measured in all cases, and alpha-FP value was raised in 77 (89.5%) cases, whereas beta-HCG was high in 5 cases (5.81%). The Overall Survival (OS) and Disease-Free Survival (DFS) in our study was 90.7%.
Conclusion: The clinical profile of GCTs in our study population is similar to those reported in other Asian and European studies. Our analysis points out age as the most critical determinant in the prognosis of pediatric GCT. Although Factors like serum AFP greater than 10,000 ng/ml and metastatic disease were associated with poor prognosis, we could not prove statistical significance due to the limited size of our study population. Therefore, multicentre prospective collaborative research is needed to ensure early diagnosis and adapt more effective treatment strategies for advanced cases.
Article Details
Work published in JPMI is licensed under a
Creative Commons Attribution-NonCommercial 2.0 Generic License.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
References
Shafique F, Ali S, Almansouri T, Van Eeden F, Shafi N, Khalid M, Khawaja S, Andleeb S, Hassan MU. Thalassemia, a human blood disorder. Braz J Biol. 2021;83:e246062. DOI: 10.1590/1519-6984.246062.
Al-Moshary M, Al-Mussaed E, Khan A. Prevalence of transfusion transmitted infections and the quality of life in beta-thalassemia major patients. Cureus. 2019;11(11):e6129.
Khaliq S. Thalassemia in Pakistan. Hemoglobin. 2022;46(1):12-4.
Ansari SH, Shamsi TS, Ashraf M, et al. Molecular epidemiology of beta-thalassemia in Pakistan: Far-reaching implications. Int J Mol Epidemiol Genet. 2011;2(4):403-8.
Ahmed S, Jafri H, Rashid Y, et al. Cascade screening for beta-thalassemia in Pakistan: Development, feasibility, and acceptability of a decision support intervention for relatives. Eur J Hum Genet. 2022;30(1):73-80.
d'Arqom A, M GP, Savitri Y, et al. Vitamin and mineral supplementation for beta-thalassemia during the COVID-19 pandemic. Future Sci OA. 2020;6(9):FSO628.
Singla H, GG. Role of estimation of serum ferritin, vitamin B12, and folic acid in the management of beta-thalassemic children. Int J Med Res Rev. 2016;4(8):1476-83.
Karimi M, Cohan N, De Sanctis V. Thalassemia intermedia; folic acid and vitamin B12 supplementation: What we know and what is needed? Iran J Ped Hematol Oncol. 2017;7(1):57-62.
Mojtahedzadeh F, Kosaryan M, Mahdavi MR, Akbari J. The effect of folic acid supplementation in beta-thalassemia major: A randomized placebo-controlled clinical trial. Arch Iran Med. 2006;9(3):266-8.
Goyal M, Abrol P, Lal H. Parathyroid and calcium status in patients with thalassemia. Indian J Clin Biochem. 2010;25(4):385-7.
Lewis ED, Meydani SN, Wu D. Regulatory role of vitamin E in the immune system and inflammation. IUBMB Life. 2019;71(4):487-94.
Rachmilewitz EA, Shifter A, Kahane I. Vitamin E deficiency in beta-thalassemia major: Changes in hematological and biochemical parameters after a therapeutic trial with alpha-tocopherol. Am J Clin Nutr. 1979;32(9):1850-8.
Cárdenas EMB. Bioinformatic analysis of insertion, deletion, and substitution mutations in the human beta-globin gene. Comput Mol Biosci. 2021;11(1).
Green R, Datta Mitra A. Megaloblastic anemias: Nutritional and other causes. Med Clin North Am. 2017;101(2):297-317.
Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9(11):799-809.
Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-23.
Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823(9):1434-43.
Means RT Jr. Pathogenesis of the anemia of chronic disease: A cytokine-mediated anemia. Stem Cells. 1995;13(1):32-7.
Taher AT, Cappellini MD, Musallam KM. Recent advances and treatment challenges in patients with non-transfusion-dependent thalassemia. Blood Rev. 2012;26 Suppl 1:S1-2.
Tripathi G, Kalra M, Mahajan A. Folate supplementation in transfusion-dependent thalassemia: Do we really need such high doses? Indian J Med Paediatr Oncol. 2016;37(4):305.
Williams BA, McCartney H, Adams E, Devlin AM, Singer J, Vercauteren S, Wu JK, Karakochuk CD. Folic acid supplementation in children with sickle cell disease: Study protocol for a double-blind randomized cross-over trial. Trials. 2020;21(1):593.
Bove-Fenderson E, Mannstadt M. Hypocalcemic disorders. Best Pract Res Clin Endocrinol Metab. 2018;32(5):639-56.
Nagy M, Mastenbroek TG, Mattheij NJA, de Witt S, Clemetson KJ, Kirschner J, Schulz AS, Vraetz T, Speckmann C, Braun A, Cosemans JMEM, Zieger B, Heemskerk JWM. Variable impairment of platelet functions in patients with severe, genetically linked immune deficiencies. Haematologica. 2018;103(3):540-9.
Santra S, Sharma K, Dash I, Mondal S, Mondal H. Bone mineral density, serum calcium, and vitamin D levels in adult thalassemia major patients: Experience from a single center in Eastern India. Cureus. 2022;14(7):e26688.
Stefanopoulos D, Papaioannou NA, Papavassiliou AG, Mastorakos G, Vryonidou A, Michou A, Dontas IA, Lyritis G, Kassi E, Tournis S. A contemporary therapeutic approach to bone disease in beta-thalassemia: A review. J Frailty Sarcopenia Falls. 2018;3(1):13-25.
Jilani T, Iqbal MP. Vitamin E deficiency in South Asian population and the therapeutic use of alpha-tocopherol (Vitamin E) for correction of anemia. Pak J Med Sci. 2018;34(6):1571-5.
Violi F, Pignatelli P, Basili S. Nutrition, supplements, and vitamins in platelet function and bleeding. Circulation. 2010;121(8):1033-44.
Rizvi S, Raza ST, Ahmed F, Ahmad A, Abbas S, Mahdi F. The role of vitamin E in human health and some diseases. Sultan Qaboos Univ Med J. 2014;14(2):e157-65.
Pronai W, Riegler-Keil M, Silberbauer K, Stockenhuber F. Folic acid supplementation improves erythropoietin response. Nephron. 1995;71(4):395-400.
Traber MG, Atkinson J. Vitamin E: Antioxidant and nothing more. Free Radic Biol Med. 2007;43(1):4-15.
Socha DS, DeSouza SI, Flagg A, et al. Severe megaloblastic anemia: Vitamin deficiency and other causes. Cleve Clin J Med. 2020;87(3):153-64.